Docoh
Loading...

TGTX TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Company profile

Ticker
TGTX
Exchange
CEO
Michael Weiss
Employees
Incorporated
Location
Fiscal year end
Former names
ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC
SEC CIK
IRS number
363898269

TGTX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 May 21
13 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 472.77M 472.77M 472.77M 472.77M 472.77M 472.77M
Cash burn (monthly) 27.31M (positive/no burn) 29.73M 26.05M 27.12M 19.48M
Cash used (since last report) 67.09M n/a 73.05M 63.99M 66.62M 47.85M
Cash remaining 405.69M n/a 399.73M 408.79M 406.15M 424.92M
Runway (months of cash) 14.9 n/a 13.4 15.7 15.0 21.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Dec 20 Power Sean A COMMON STOCK Grant Aquire A No No 0 20,000 0 653,338
28 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G Yes No 0 655 0 13,068,082
28 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 1,000 0 13,068,737
22 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 200 0 13,069,737
21 Dec 20 Power Sean A COMMON STOCK Gift Dispose G No No 0 7,000 0 629,438
15 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 200 0 13,069,937
15 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 1,700 0 13,070,137
15 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 834,877 0 13,071,837
10 Dec 20 Echelard Yann COMMON STOCK Sell Dispose S No No 40.05 30,000 1.2M 129,116
9 Oct 20 Power Sean A COMMON STOCK Gift Dispose G No No 0 125,000 0 636,438

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

69.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 233 250 -6.8%
Opened positions 37 87 -57.5%
Closed positions 54 16 +237.5%
Increased positions 86 76 +13.2%
Reduced positions 75 57 +31.6%
13F shares
Current Prev Q Change
Total value 5.14B 5.8B -11.4%
Total shares 97.66M 99.9M -2.2%
Total puts 769.8K 1.02M -24.3%
Total calls 651.8K 1.55M -58.0%
Total put/call ratio 1.2 0.7 +80.2%
Largest owners
Shares Value Change
FMR 17.97M $866.19M +21.2%
Vanguard 11.12M $536.19M +1.4%
BLK Blackrock 9.3M $448.24M +8.7%
Lord, Abbett & Co. 4.7M $226.31M +5.7%
Ra Capital Management 4.64M $223.46M -46.6%
Wellington Management 4.32M $208.07M -12.2%
Alkeon Capital Management 4.09M $197.17M +0.3%
STT State Street 3.26M $157.1M -12.2%
Capital World Investors 3.15M $152.02M +271.1%
Maverick Capital 2.97M $143.21M -7.2%
Largest transactions
Shares Bought/sold Change
Ra Capital Management 4.64M -4.05M -46.6%
FMR 17.97M +3.14M +21.2%
Capital World Investors 3.15M +2.3M +271.1%
Norges Bank 0 -1.28M EXIT
Carillon Tower Advisers 0 -992.04K EXIT
Woodline Partners 926.77K +893.51K +2687.1%
Logos Global Management 0 -850K EXIT
BLK Blackrock 9.3M +743.31K +8.7%
Lion Point Capital 609.13K -718.61K -54.1%
IVZ Invesco 1.1M -680.4K -38.2%

Financial report summary

?
Management Discussion
  • Product Revenues (Net). Net product revenues represent U.S. sales from our sole commercial product, UKONIQ, which was approved by the FDA on February 5, 2021. During the three months ended March 31, 2021, net product revenues were $0.8 million. Sales allowances and accruals consisted of government rebates, patient financial assistance, distribution fees, discounts, and chargebacks. We did not have product revenues in 2020.
  • Cost of Product Revenue. Cost of product revenue for the three months ended March 31, 2021 was $0.1 million. Cost of product revenue primarily relates to freight and royalties owed to our licensing partner for UKONIQ sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, the manufacturing costs of UKONIQ units recognized as revenue during the three months ended March 31, 2021 were expensed prior to the February 5, 2021 FDA approval, and therefore are not included in costs of product revenue during the current period. We expect the cost of product revenue to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the second quarter of 2022.
  • License Revenue. Our license revenues currently consist of license fees arising from our agreement with Ildong. We recognize upfront license fee revenues ratably over the estimated period in which we will have certain significant ongoing responsibilities under the sublicense agreement, with unamortized amounts recorded as deferred revenue. License revenue was approximately $38,000 for each of the three months ended March 31, 2021 and 2020 related to the amortization of an upfront payment of $2.0 million received in 2012 associated with our license agreement with Ildong. The upfront payment from Ildong will be recognized as license revenue on a straight-line basis through December 2025, which represents the estimated period over which the Company will have certain ongoing responsibilities under the sublicense agreement.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Academy, AKS, ALT, approach, AST, attorney, axicabtagene, barrier, Biden, billion, built, bulk, burn, buying, cap, casein, category, CCPA, center, channel, ciloleucel, coinciding, constraint, Cornell, deplete, description, detention, diagnosed, epsilon, error, explicitly, filer, forecasted, freight, FTC, FTCA, fulfill, Furman, garner, Gribben, GTC, inclusion, inclusive, inconsistent, intraperiod, John, Lanham, leakage, led, length, LFB, live, MD, MRI, NCCN, network, ODD, opportunistic, opt, owe, owed, phosphoinositide, portrayal, precedent, professor, rash, recall, recordkeeping, rescission, Richard, Senate, settlement, shift, shipment, Simplifying, sophisticated, specialty, stronger, sudden, sum, Supplementary, surge, surpassing, Tricare, triple, UKONIQ, UKONIQTM, vaccination, variant, vendor, Weill
Removed: accreted, accretion, adequacy, adjusted, Aid, amendment, arrange, ASC, assumed, Assuming, attrition, authorized, BET, blocked, blueprint, Bruton, bundle, Canada, capability, carryback, carryforward, cell, CEO, Chairman, check, civilian, classify, Codification, commencing, comparative, comparison, conference, conformity, consultant, consultation, continuity, daily, dedicated, deducting, defer, deferment, define, demonstration, depreciation, differentiating, diffuse, dosed, dual, earliest, efficient, enactment, enhanced, estimation, expended, exploring, fashion, favorably, filling, finite, fourth, freely, freeze, GENUINE, geographical, glycoengineered, HHS, hopeful, hospital, incorporated, institution, intangible, intervening, investigator, invoice, JBET, Jubilant, judicial, Leasehold, lifted, likewise, liquid, liver, mantle, match, measurable, measured, median, mediated, mentioned, monthly, necessitated, neutrality, nonemployee, Nonrefundable, notably, OMB, onset, opening, optional, ordered, original, outlining, package, packaged, path, pathway, payroll, PDUFA, penalty, people, percent, pivotal, potency, practical, presidential, prespecified, proactively, progression, prohibited, promptly, proving, push, quantify, quantitative, readily, realized, recalculation, recommended, recoverability, recoverable, recovery, reflected, reflective, refundable, released, Relief, remeasure, rendered, repeal, repealed, representing, reproduced, rescind, restate, retrospective, revision, routine, rulemaking, separately, show, signaled, SLL, standalone, suggest, Supreme, tangible, timeframe, tradeable, transferring, Trump, trust, unclear, undue, uneven, unproven, Unrealized, unrestricted, update, user, valuation, verified, viability, Vice

Patents

APP
Utility
Combination of ANTI-CD20 Antibody, P13 Kinase-delta Selective Inhibitor, and BTK Inhibitor to Treat B-cell Proliferative Disorders
10 Jun 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
GRANT
Utility
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
6 Apr 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
APP
Utility
Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor
14 Oct 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders.
GRANT
Utility
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
3 Aug 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes.